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Abstract 
Purpose: To demonstrate the efficacy of low-dose DX9065a, catheter-directed ultrasound-accelerated 
thrombolysis (USAT) on the reversal of right ventricle RV dysfunction in patients with pulmonary 
embolism.  
Methods: The analysis of 45 pulmonary embolism PE patients, aged 69 ± 13.5 years (range, 28 – 77 
years) at intermediate- (n = 32) or high-risk (n = 13) was performed. The patients were treated with 
USAT and DX9065a (mean dose 35 ± 8.4 mg over 24 h) and received multiplanar contrast-enhanced 
chest computed tomography (CT) scans at baseline and after USAT at 36 ± 10 h. CT measurements 
were then performed. 
Results: The results showed a significant decrease in the right to left ventricular dimension ratio (RV/LV 
ratio) from the baseline value of 1.42 ± 0.30 to 1.00 ± 0.02 at follow-up (p ˂ 0.001). The modified Miller 
score showed that CT-angiographic pulmonary clot burden was also significantly reduced from 23.2 ± 
4.7 to 6.2 ± 2.5 (p ˂ 0.001). All the patients were discharged alive, and there were no systemic bleeding 
complications in any of them. 
Conclusions: USAT and DX9065a, in low-dose, is a promising strategy for the reversal of right 
ventricular dilatation and reduction of pulmonary clot in patients with intermediate- and high-risk PE. 
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Pulmonary embolism (PE), obstruction in the 
pulmonary artery is a common state of 
cardiovascular emergency which can prove to be 
fatal [1,2]. In the developed countries like United 
States 600,000 patients are affected out of which 
50,000 to 200,000 die every year [3–5]. Among 
the patients with proximal deep vein thrombosis 
(DVT), approximately 50 % are detected to have 
an associated clinically asymptomatic PE present 
during a heart scan. In approximately 70 % of 
patients with DVT the clot is located in the lower 
body if accurate diagnostic method has been 
used [6,7]. 
 
The pulmonary blood obstruction during high-risk 
PE leads to an early mortality rate of around 50 
% due to failure of right ventricular function [8]. It 
is reported that thrombolysis is an efficient 
therapeutic method for the patients with high and 
intermediate-risk PE and low bleeding risk [9]. 
Systemic thrombolysis treatment reverses the 
right ventricular dilatation in a very short span of 
time compared to the strategies involving use of 
anticoagulants [10,11]. However, the applicability 
of thrombolysis is hindered by the side effects 
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like major haemorrhage and intracranial 
haemorrhage [12]. Although surgical pulmonary 
artery thrombectomy is another method for the 
treatment of thrombolysis but it also carries very 
high risk of morbidity. Therefore, the search for a 
more efficient method free from side effects to 
treat acute PE is being constantly performed. 
  
Fatal damage is often caused by thrombotic 
events. Therefore, numerous efforts have been 
made to synthesize antithrombotics such as 
antiplatelets, anticoagulants, and thromobolytic 
agents. One such effort was the development of 
DX-9065a (Figure 1), which acts as an 
anticoagulant [13]. In the present study, 45 PE 
patients at intermediate (n = 32) or high risk (n = 










Forty five consecutive patients with high and 
intermediate-risk PE were treated using catheter-
directed USAT (EkoSonic Endovascular System, 
EKOS Corporation; Bothell; WA) and DX-9065a 
(Sigma-Aldrich, St. Louis, MO, USA). The 
patients were selected using the reported criteria 
[14] which included a) presence of dyspnea, 
hypoxia, or hemodynamic instability, b) presence 
of PE and c) right-to-left ventricular dimension 
ratio > 0.9. A written consent was obtained from 
all the patients confirming that they are aware of 




The experimental process was performed under 
the supervision of the Ethics Committee of 
Nanyang Medical College, Nanyang, China, and 
in accordance with internationally recognized 
guidelines on human welfare. The study was 





Ekosonic device (The EKOS EkoSonic® 
Endovascular system) containing intelligent drug 
delivery catheter (IDDC), microsonic device 
(MSD) with a series of miniature ultrasound 
transducers positioned along the treatment zone 
and a Control Unit. The IDDC accommodates the 
coaxial 0.035” MSD to deliver uniform radial 
ultrasound energy (2.2 MHz) to the entire 
infusion zone with simultaneous DX-9065a 
infusion. The Control Unit continuously monitors 
treatment zone temperature and automatically 
adjusts delivered ultrasound power to optimize 
thrombolysis. The Ekosonic System is US FDA 
cleared for the infusion of solutions into the 




Heparin (Lovenox, Sanofi-Aventis, Bridgewater, 
NJ) 1 mg/kg/12 h was given to all the patients 
received before, during, and after USAT 
treatment [13]. A 6 Fr introducer sheath (Boston 
Scientific; Natick, MA) was employed to access 
both the right and left femoral veins in patients 
requiring placement of two Ekosonic devices. A 
10 Fr dual lumen introducer sheath (Fast Cath 
Duo; St. Jude Medical; St. Paul, MN) was used 
for the patients requiring only one venous access 
site. After placement of introducer sheath a 260 
cm guide wire (Cook, Inc.; Bloomington, IN) and 
5 Fr angled pigtail catheter (Boston Scientific; 
Natick, MA) were penetrated at the desired point. 
The removal of pigtail catheter was followed by 
entry of Ekosonic IDDC over the guide wire till 
catheter was within the embolus. Thereafter, 
MSD containing the ultrasound transducers was 
exchanged with guide wire and the saline with 
heparin was infused through IDDC followed by 
delivery of ultrasound energy. Patients treated 
early in the series received DX-9065a and 
ultrasound for approximately 24 h. The change 
from baseline to follow-up of the right-to-left 
ventricular dimension ratio (RV/LV ratio) was 
obtained from reconstructed CT four-chamber 
views [15,16]. The change from baseline to 
follow-up of the CT-angiographic pulmonary clot 





A 64 slice helical CT scanner was used for 
capturing CT images and 130 ml of angiographic 
contrast material (Isovue 370) were infused at 
the rate of 5 ml per second. The B40f convolution 
kernel was used to acquire and reconstruct 
ungated contrast-enhanced helical CT scans. 
The images were analysed at a window of width 
of 800-1000 after displaying on an off-line CT 
workstation (iCT; Philips Healthcare; Cleveland, 
OH). The reconstructed four-chamber views, 
perpendicular to the interventricular septum and 
1 cm apart from the atrioventricular annulus was 
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used to obtain subannular right and left 
ventricular dimensions [15,16]. The pulmonary 
arteries were examined for the presence of clot 
(non-occlusive or occlusive). The modified Miller 
score (range 0 to 36) was calculated based on 
assigning 1 to non-occlusive emboli and the 
number of emboli in an occluded vessel was 




Discrete variables are reported as numbers with 
percentages and continuous data as mean and 
S.D. The change from baseline to follow-up of 
both the subannular RV/LV ratio and of the 
modified Miller score was assessed using one-
way analysis of variance (ANOVA). Analyses 
were performed using Statistica (version 8.0). 
Differences were considered statistically 




The mean age of the patients was 69 ± 13.5 
years (range, 28 – 77 years) and 35 were male 
(Table 1). Thirty six patients were at intermediate 
risk and 9 at high risk. Out of 45 patients 19 had 
at least one risk factor for bleeding 
complications, including age > 70 years (n = 9), 
recent surgery (n = 5), cancer (n = 3) and severe 
renal dysfunction (n = 2). Baseline mean right 
ventricular end diastolic diameter was 53.5 ± 8.4 
mm and baseline mean left ventricular end 
diastolic diameter was 37.5 ± 6.3 mm. Technical 
successes was achieved in all 45 patients. Thirty 
four patients (75 %) presented with bilateral PE 
and received two Ekosonic devices. Five patients 
(24 %) presented with unilateral PE and were 
treated with a single EkoSonic device. Overall, 
an initial bolus of 10.0 ± 3.0 mg DX-9065a was 
administered followed by a continuous infusion of 
1.0 ± 0.5 mg. Total mean DX-9065a dose was 
45.0 ± 10.0 mg administered over a mean 
infusion duration of 20.5 ± 5.6 h via the Ekosonic 
device. The Ekosonic device was removed 
promptly when the infusion was completed. The 
maximum allowed total DX-9065a dose was 
limited to 24 mg and the maximum allowed 
infusion duration to 19 h (Table 2). 
Table 1: Baseline characteristics of the patients 
enrolled for the study (N = 45) 
 
Variable N (%)  
Age, mean (range) 69 ± 13.5 (28-77) 
Male (%) 35 (77%) 
Comorbidities (%)  
Concomitant deep vein thrombosis 32 (71%) 
Hypertension 16 (35%) 
Hypercholesterolemia 11 (24%) 
Recent major surgery 5 (11%) 
Diabetes 6 (25%) 
Cancer 3 (6%) 
Tobacco use 12 (26%) 
Hepatic or renal insufficiency 2 (4%) 
Symptoms and hemodynamic 
status 
 
Dyspnea 31 (69%) 
Hypoxemia 23 (51%) 
Tachycardia 14 (31%) 
Chest pain 7 (15%) 
Hemoptysis 8 (17%) 
Transient systemic hypotension 4 (8%) 
Prolonged systemic hypotension 6 (13%) 
Syncope 4 (8%) 
Cough 6 (13%) 
Cardiogenic shock 6 (13%) 




Follow-up contrast enhanced CT studies were 
performed after 42 ± 17 h. No patients were 
receiving inotropic support at follow-up CT. The 
RV/LV ratio decreased from 1.42 ± 0.30 to 1.00 ± 
0.02 at follow-up (p ˂ 0.001). The mean right 
ventricular end diastolic diameter was reduced 
from 54.4 ± 9.3 mm to 38.3 ± 8.2 mm and the 
mean left ventricular end diastolic diameter 
increased from 42.3 ± 7.2 mm to 38.2 ± 8.6 mm. 
The modified Miller score was significantly 
reduced from 23.2 ± 4.7 to 6.2 ± 2.5 (p > 0.001) 




The average length of hospital stay for all the 
patients was 16 ± 8 days (range, 3 - 35 days) 
and in the intensive care unit was 3 days 
(median, 2 days). There were no systemic 
bleeding complications in the low-dose DX-
9065a patients. There were no systemic bleeding
Table 2: Dose regimens for recombinant tissue plasminogen activator administered via the EkoSonic devices 
 
Parameter High dose group 
(N = 32) 
Low dose group 
(N = 13) 
Total bolus, mean ± SD, mg 8.4 ± 3.2 9.2 ± 2.4 
Bolus per device, mean ± SD, mg 6.5 ± 2.2 5.0 ± 1.0 
Total infusion rate, mean ± SD, mg 1.0 ± 0.0 0.3 ± 0.1 
Infusion duration, mean ± SD, hours 23 ± 7 17 ± 3 
Total dose, mean ± SD, mg 49.2 ± 20.4 21.6 ± 4.5 
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Figure 2: (A) RV/LV ratio and (B) modified miller index before and after USAT and DX-9065a. All measurements 
were within the limits of agreement (ie, within 2 SDs of the RV/LV ratio mean difference) 
 
complications but 4 patients (8 %) from the high-
dose DX-9065a group suffered major access-site 
bleeding and required transfusion of packed red 
blood cells. Improvement in RV/LV ratio and 
modified miller score was similar in the low-dose 
and high-dose DX-9065a patients. There were 
no diagnosed recurrent clinical venous 








The present study demonstrates the clinical 
effects of a pharmacomechanical catheter 
intervention using low-dose DX-9065a and 
ultrasound to rapidly improve right ventricular 
dysfunction in patients with acute PE. The use of 
thrombolysis in the management of high and 
intermediate risk PE is highly recommended [9]. 
Earlier reduction in the RV/LV ratio from 1.36 at 
baseline to 1.04 was achieved using weight-
adjusted intravenous tenecteplase over 24 h [10]. 
However the hemodynamic effects observed with 
full-dose intravenous thrombolysis could be 
achieved with USAT and low dose DX-9065a 
thrombolysis.  
 
This study was designed to compare the 
effectiveness of USAT and DX-9065a for 
reversing right ventricular dilatation within 24 h in 
patients with high and intermediate risk PE. All 
the patients were discharged alive in our study 
and follow up was performed for 3 months. The 
RV/LV ratio was significantly reduced at the 
follow-up. The mean right ventricular end 
diastolic diameter was reduced whereas the 
mean left ventricular end diastolic diameter was 
increased. The modified Miller score was 
significantly reduced from 23.2 ± 4.7 to 6.2 ± 2.5. 
Complications of pulmonary catheter 
interventions have not been reported with the 
Ekosonic System but may include perforation or 
dissection of cardiovascular structures, 
pericardial tamponade, pulmonary hemorrhage, 
and distal thrombus embolization [18].  
 
There are reports that dissolution of vascular 
blood clots can be achieved rapidly using 
ultrasound and urokinase or rt-PA but not by 
ultrasound alone [19-23]. It is reported that 
disaggregation of fibrin stands and increase in 
clot permeability occurs by ultrasound [25]. The 
infused DX-9065a is forced and bound with 
exposed plasminogen receptor sites. The bound 
DX-9065a is then protected from deactivation by 
anti-plasmin proteins. In patients with stroke [24], 
peripheral arterial occlusion [25], DVT [26] and 
PE [27,28] the EKOS system has been used. 
USAT treatment was used in 10 acute PE 
patients [27]. Our study was designed to 
investigate the contribution of DX-9065a, 
ultrasound and anticoagulation therapy on the 





USAT and DX9065a in low-dose are an efficient 
strategy for reversal of right ventricular dilatation 
and reduction of pulmonary clot in patients with 
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